Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2018

Open Access 01-12-2018 | Original research

Evaluation of D-isomers of 4-borono-2-18F-fluoro-phenylalanine and O-11C-methyl-tyrosine as brain tumor imaging agents: a comparative PET study with their L-isomers in rat brain glioma

Authors: Masakatsu Kanazawa, Shingo Nishiyama, Fumio Hashimoto, Takeharu Kakiuchi, Hideo Tsukada

Published in: EJNMMI Research | Issue 1/2018

Login to get access

Abstract

Background

The potential of the D-isomerization of 4-borono-2-18F-fluoro-phenylalanine (18F-FBPA) to improve its target tumor to non-target normal brain tissue ratio (TBR) was evaluated in rat brain glioma and compared with those of L- and D-11C-methyl-tyrosine (11C-CMT).
The L- or D-isomer of 18F-FBPA was injected into rats through the tail vein, and their whole body kinetics and distributions were assessed using the tissue dissection method up to 90 min after the injection. The kinetics of L- and D-18F-FBPA or L- and D-11C-CMT in the C-6 glioma-inoculated rat brain were measured for 90 or 60 min, respectively, using high-resolution animal PET, and their TBRs were assessed.

Results

Tissue dissection analyses showed that D-18F-FBPA uptake was significantly lower than that of L-18F-FBPA in the brain and abdominal organs, except for the kidney and bladder, reflecting the faster elimination rate of D-18F-FBPA than L-18F-FBPA from the blood to the urinary tract. PET imaging using 18F-FBPA revealed that although the brain uptake of D-18F-FBPA was significantly lower than that of L-18F-FBPA, the TBR of the D-isomer improved to 6.93 from 1.45 for the L-isomer. Similar results were obtained with PET imaging using 11C-CMT with a smaller improvement in TBR to 1.75 for D-11C-CMT from 1.33 for L-11C-CMT.

Conclusions

The present results indicate that D-18F-FBPA is a better brain tumor imaging agent with higher TBR than its original L-isomer and previously reported tyrosine-based PET imaging agents. This improved TBR of D-18F-FBPA without any pre-treatments, such as tentative blood-brain barrier disruption using hyperosmotic agents or sonication, suggests that the D-isomerization of BPA results in the more selective accumulation of 10B in tumor cells that is more effective and less toxic than conventional L-BPA.
Literature
1.
Pisarev MA, Dagrosa MA, Juvenal GJ. Boron neutron capture therapy in cancer: past, present and future. Arq Bras Endocrinol Metabol. 2007;51:852–6.CrossRefPubMed
2.
Soloway AH, Hatanaka H, Davis MA. Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds. J Med Chem. 1967;10:714–7.CrossRefPubMed
3.
Mishima Y, Honda T, Ichihashi M, Obara H, Hiratsuka J, Fukuda H, Karashima H, Kobayashi T, Kanda K, Yoshino K. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound. Lancet. 1989;2:388–9.CrossRefPubMed
4.
Barth RF, Yang W, Bartus RT, Moeschberger ML, Joel DD, Nawrocky MM, Goodman JH, Soloway AH. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res. 1997;57:1129–36.PubMed
5.
Yoshida F, Matsumura A, Yamamoto T, Kumada H, Nakai K. Enhancement of sodium borocaptate (BSH) uptake by tumor cells induced by glutathione depletion and its radiobiological effect. Cancer Lett. 2004;215:61–7.CrossRefPubMed
6.
Yokoyama K, Miyatake S, Kajimoto Y, Kawabata S, Doi A, Yoshida T, Asano T, Kirihata M, Ono K, Kuroiwa T. Pharmacokinetic study of BSH and BPA in simultaneous use for BNCT. J Neuro-Oncol. 2006;78:227–32.CrossRef
7.
Ishiwata K, Ido T, Mejia AA, Ichihashi M, Mishima Y. Synthesis and radiation dosimetry of 4-borono-2-[18F]fluoro-D,L-phenylalanine: a target compound for PET and boron neutron capture therapy. Int J Rad Appl Instrum A. 1991;42:325–8.CrossRefPubMed
8.
Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, Ido T. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med. 1998;39:325–33.PubMed
9.
Wang H-E, Wu S-Y, Chang C-W, Liu R-S, Hwang L-C, Lee T-W, Chen J-C, Hwang J-J. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model. Nucl Med Biol. 2005;32:367–75.CrossRefPubMed
10.
Hanaoka K, Watabe T, Naka S, Kanai Y, Ikeda H, Horitsugi G, Kato H, Isohashi K, Shimosegawa E, Hatazawa J. FBPA PET in boron neutron capture therapy for cancer: prediction of 10B concentration in the tumor and normal tissue in a rat xenograft model. EJNMMI Res. 2014;4:70.CrossRefPubMedPubMedCentral
11.
Watabe T, Ikeda H, Nagamori S, Wiriyasermkul P, Tanaka Y, Naka S, Kanai Y, Hagiwara K, Aoki M, Shimosegawa E, Hatazawa J. 18F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with 18F-FDG and 11C-methionine PET. Eur J Nucl Med Mol Imaging. 2017;44:321–31.CrossRefPubMed
12.
Yoshimoto M, Kurihara H, Honda N, Kawai K, Ohe K, Fujii H, Itami J, Yasuaki Arai Y. Predominant contribution of L-type amino acid transporter to 4-borono-2-18F-fluoro-phenylalanine uptake in human glioblastoma cells. Nucl Med Biol. 2013;40:625–9.CrossRefPubMed
13.
Wongthai P, Hagiwara K, Miyoshi Y, Wiriyasermkul P, Wei L, Ohgaki R, Kato I, Hamase K, Nagamori S, Kanai Y. Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2. Cancer Sci. 2015;106:279–86.CrossRefPubMedPubMedCentral
14.
Kanai Y, Endou H. Heterodimeric amino acid transporters: molecular biology and pathological and pharmacological relevance. Curr Drug Metab. 2001;2:339–54.CrossRefPubMed
15.
Hsieh C-H, Chen Y-F, Chen F-D, Hwang J-J, Chen J-C, Liu R-S, Kai J-J, Chang C-W, Wang H-E. Evaluation of pharmacokinetics of 4-borono-2-18F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. J Nucl Med. 2005;46:1858–65.PubMed
16.
Yang F-Y, Chang W-Y, Li J-J, Wang H-E, Chen J-C, Chang C-W. Pharmacokinetic analysis and uptake of 18F-FBPA-Fr after ultrasound-induced blood-brain barrier disruption for potential enhancement of boron delivery for neutron capture therapy. J Nucl Med. 2014;55:616–21.CrossRefPubMed
17.
Tsukada H, Sato K, Fukumoto D, Nishiyama S, Harada N, Kakiuchi T. Evaluation of D-isomers of O-11C-methyl tyrosine and O-18F-fluoromethyl tyrosine as tumor-imaging agents in tumor-bearing mice: comparison with L- and D-11C-methionine. J Nucl Med. 2006;47:679–88.PubMed
18.
Tsukada H, Sato K, Fukumoto D, Kakiuchi T. Evaluation of D-isomers of O-18F-fluoromethyl, O-18F-fluoroethyl and O-18F-fluoropropyl tyrosine as tumour imaging agents in mice. Eur J Nucl Med Mol Imaging. 2006;33:1017–24.CrossRefPubMed
19.
Urakami T, Sakai K, Asai T, Fukumoto D, Tsukada H, Oku N. Evaluation of O-[18F]fluoromethyl-D-tyrosine as a radiotracer for tumor imaging with positron emission tomography. Nucl Med Biol. 2009;36:295–303.CrossRefPubMed
20.
Murayama C, Harada N, Kakiuchi T, Fukumoto D, Kamijo A, Kawaguchi AT, Tsukada H. Evaluation of D-18F-FMT, 18F-FDG, L-11C-MET, and 18F-FLT for monitoring the response of tumors to radiotherapy in mice. J Nucl Med. 2009;50:290–5.CrossRefPubMed
21.
Zitzmann-Kolbe S, Strube A, Frisk A-L, Kakonen S-M, Tsukada H, Hauff P, Berndorff D, Graham K. D-18F-Fluoromethyl tyrosine imaging of bone metastases in a mouse model. J Nucl Med. 2010;51:1632–6.CrossRefPubMed
22.
Stegink LD, Moss J, Printen KJ, Cho ES. D-methionine utilization in adult monkeys fed diets containing DL-methionine. J Nutr. 1980;110:1240–6.CrossRefPubMed
23.
Ishiwata K, Vaalburg W, Elsinga PH, Paans AMJ, Woldring MG. Comparison of L-[1-11C]methionine and L-methyl-[11C]methionine for measuring in vivo protein synthesis rates with PET. J Nucl Med. 1988;29:1419–27.PubMed
24.
Tanaka E, Kudo H. Optimal relaxation parameters of DRAMA (dynamic RAMLA) aiming at one-pass image reconstruction for 3D-PET. Phys Med Biol. 2010;55:2917–39.CrossRefPubMed
25.
Vaalburg W, Coenen HH, Crouzel C, Elsinga PH, Långström B, Lemaire C, Meyer GJ. Amino acids for the measurement of protein synthesis in vivo by PET. Nucl Med Biol. 1992;19:227–37.
26.
Ishiwata K, Kawamura K, Wang WF, Furumoto S, Kubota K, Pascali C, Bogni A, Iwata R. Evaluation of O-[11C]methyl-L-tyrosine and O-[18F]fluoromethyl-L-tyrosine as tumor imaging tracers by PET. Nucl Med Biol. 2004;31:191–8.CrossRefPubMed
27.
Schober O, Duden C, Meyer GJ, Muller JA, Hundeshagen H. Non selective transport of [11C-methyl]-L- and D-methionine into a malignant glioma. Eur J Nucl Med. 1987;13:103–5.CrossRefPubMed
28.
Bergström M, Lundqvist H, Ericson K, Lilia A, Johnström P, Långström B, von Holst H, Eriksson L, Bromqvist G. Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain tumor studies with positron emission tomography. Acta Radiol. 1987;28:225–9.PubMed
29.
Stegmayr C, Oliveira D, Niemietz N, Willuweit A, Lohmann P, Galldiks N, Shah NJ, Ermert J, Langen K-J. Influence of bevacizumab on blood-brain barrier permeability and O-(2-18F-fluoroethyl)-L-tyrosine uptake in rat gliomas. J Nucl Med. 2017;58:700–5.CrossRefPubMed
30.
Nakagawa Y, Hatanaka H. Boron neutron capture therapy: clinical brain tumor studies. J Neuro-Oncol. 1997;33:105–15.CrossRef
31.
Joensuu H, Kankaanranta L, Seppala T, Auterinen I, Kallio M, Kulvik M. Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine. J Neuro-Oncol. 2003;61:123–34.
32.
Behnia R, Koushanpour E, Brunner EA. Effects of hyperosmotic mannitol infusion on hemodynamics of dog kidney. Anesth Analg. 1996;82:902–8.PubMed
Metadata
Title
Evaluation of D-isomers of 4-borono-2-18F-fluoro-phenylalanine and O-11C-methyl-tyrosine as brain tumor imaging agents: a comparative PET study with their L-isomers in rat brain glioma
Authors
Masakatsu Kanazawa
Shingo Nishiyama
Fumio Hashimoto
Takeharu Kakiuchi
Hideo Tsukada
Publication date
01-12-2018
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2018
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-018-0404-6

Other articles of this Issue 1/2018

EJNMMI Research 1/2018 Go to the issue

Short communication

18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model

Original research

A novel genomic signature predicting FDG uptake in diverse metastatic tumors

Original research

Uniform intratumoral distribution of radioactivity produced using two different radioagents, 64Cu-cyclam-RAFT-c(-RGDfK-)4 and 64Cu-ATSM, improves therapeutic efficacy in a small animal tumor model

Original research

Sensitive and early detection of mitochondrial dysfunction in the liver of NASH model mice by PET imaging with 18F-BCPP-BF

Original research

Imaging Aβ and tau in early stage Alzheimer’s disease with [18F]AV45 and [18F]AV1451

Original Research

Volume of interest delineation techniques for 18F-FDG PET-CT scans during neoadjuvant extremity soft tissue sarcoma treatment in adults: a feasibility study